Medicare Price Negotiation: Data Needed To Establish ‘Unintended Consequences’ – CMS’ Blum
Executive Summary
US CMS principal deputy administrator Jonathan Blum challenges critics to build a 'dashboard' for tracking the impact of the negotiation program to evaluate whether it will hamper access to needed drugs.
You may also be interested in...
Medicare Drug Price Inflation Rebate Invoice Distribution Will Start In 2025, CMS Says
Coinsurance for Part B drugs may reflect rebates by April, and sponsors are already liable for them, but payments will be delayed several years as CMS develops its systems. Agency seeks comment on how to account for 340B discounts and make allowances for drug shortages, among other issues.
Medicare Price Negotiation: Special Treatment For ‘Novel Technologies’ On PhRMA’s Advocacy Agenda
Novartis CEO Vasant Narasimhan, PhRMA's incoming board chair, says in an interview that the brand drug association has a slate of issues to pursue as it works to shape the implementation of the Medicare price negotiation program in the name of preserving innovation.
Medicare Price Negotiation: Sponsors Will Have A Say, But Likely Not Sway As Timetable Comes Into Focus
CMS details when it will release information and receive public comments in the lead-up to publishing the initial list of drugs to be negotiated this fall.